Last reviewed · How we verify
Clodronate (CLODRONIC ACID)
Clodronate, also known as clodronic acid, is a small molecule drug that targets the solute carrier family 17 member 9. It belongs to the drug class of clodronic acid and is used to treat bone diseases. However, its commercial status and approved indications are unknown. Clodronate has a half-life of 43.2 hours and a low bioavailability of 1%. As a result, its use and safety considerations require further investigation.
At a glance
| Generic name | CLODRONIC ACID |
|---|---|
| Drug class | clodronic acid |
| Target | ADP/ATP translocase 1, ADP/ATP translocase 2, ADP/ATP translocase 3 |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible (PHASE3)
- Effect of Different Irrigation Protocols on Postoperative Endodontic Pain and Inflammation (NA)
- The PENTO Protocol in Medication-related Osteonecrosis of the Jaw (PHASE2)
- Clinical Trial to Assess Efficacy, Tolerability of Rising Doses of Clodronate in Painful Knee Osteoarthritis Patients (PHASE2,PHASE3)
- Combined Drug Therapy in Lateral Fragility Fractures of the Femur
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. (PHASE3)
- Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer (PHASE3)
- Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clodronate CI brief — competitive landscape report
- Clodronate updates RSS · CI watch RSS